PHA-739358 for Treatment of Hormone Refractory Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

April 30, 2011

Conditions

Metastatic Hormone Refractory Prostate Cancer

Interventions

DRUG

PHA-739358

6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle

DRUG

PHA-739358

24-hr IV infusion every 2 weeks in a 4-week cycle

Trial Locations (1)

Nerviano Medical Sciences. Clinical Research Dept., Nerviano